ArticleBlood advances2025
Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.Blood advances · 2026Article
- Pathological Allostery in ADAMTS13: Autoantibody-Induced Modulation and Its Role in Immune Thrombotic Thrombocytopenic Purpura (iTTP).Pharmaceuticals (Basel, Switzerland) · 2026Review
- Novel cryptic ADAMTS13 epitopes uncover a distinct open ADAMTS13 conformation in immune-mediated TTP.Haematologica · 2026Article
- Determining ADAMTS13 Conformation for the Diagnosis of Immune Thrombotic Thrombocytopenic Purpura and Prediction of Relapse.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Trp1250, Lys1252, and Arg1367 of ADAMTS13 comprise a hot spot for anti-CUB domain antibodies in patients with iTTP.Blood advances · 2025Article
- Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation.HemaSphere · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAllosteric regulation of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type-1 motif, member 13) activity involves an interaction between its spacer (S) and 2 complement C1r/C1s, Uegf and BMP1 (CUB; CUB1-2) domains to keep the enzyme in a closed, latent conformation. Monoclonal antibodies (mAbs) uncouple the S-CUB interaction to open the ADAMTS13 conformation and thereby disrupt the global enzyme latency. The molecular mechanism behind this mAb-induced allostery remains poorly understood. To gain insights in the mAb-induced S-CUB uncoupling and global latency disruption, we combined hydrogen/deuterium exchange mass spectrometry (HDX-MS) with structural analysis of ADAMTS13 CUB1-2 mutants. Thereby, the CUB1 L3 and L9 loops were fine-mapped as the 17G2 mAb binding epitope. Indirect S-CUB uncoupling was observed as mAb binding-induced extensive structural dynamics within both CUB1-2 domains without directly targeting the contiguous CUB1 surface that engages with the ADAMTS13 S domain. HDX-MS analysis revealed the short interdomain linker to structurally cover the central CUB1-2 domain interface, which also showed some protein regions that became more exposed upon mAb binding. Therefore, repositioning of the central CUB1-2 interface appears crucial to transfer structural dynamics between both domains. Nevertheless, mutagenesis of the short linker did not disrupt the ADAMTS13 global latency because its closed conformation was preserved. Presumably, allosteric disruption of the global latency requires a structural impact extending beyond the central interface repositioning. Because anti-ADAMTS13 autoantibodies from patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) also induce an open ADAMTS13 conformation, our novel insights in the antibody-mediated global latency disruption boost our understanding of the iTTP disease pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.